Kyverna Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Kyverna Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 429.62K shares.
- Kyverna Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 90.73K shares, a 2194.18% increase year-over-year.
- Kyverna Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 72.61K shares, a 52.61% increase year-over-year.
- Kyverna Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 523.98K shares, a 2457.89% increase year-over-year.
- Kyverna Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 600.55K shares, a 28.36% increase from fiscal 2024.
- Kyverna Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 467.87K shares, a 33.94% increase from fiscal 2023.
- Kyverna Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 349.32K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 429.62K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 1.12M shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 90.73K shares 10-Q · filed 2026-05-12 | 687.33K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 72.61K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 600.55K shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 523.98K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 575.52K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 72.02K shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 3.96K shares 10-Q · filed 2025-05-13 | 103.63K shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 47.58K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 467.87K shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 20.48K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | |
| 2024-06-30 | 31.61K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | |
| 2024-03-31 | 368.20K shares 10-Q · filed 2024-05-14 | |
| 2023-12-31 | 349.32K shares 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |